Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115479) titled 'Low-dose trifluridine/tipiracil with bevacizumab in refractory metastatic colorectal cancer: a multicenter, single-arm, phase 2 study' on Dec. 26, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Condition:
Patients with metastatic colorectal cancer who had received two or more previous chemotherapy regimens
Intervention:
Study group:Trifluridine/tipiracil (17.5 mg/m^2/dose, twice daily, days 1-10, every 2 weeks)
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2025-12-30
Target Sam...